Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID STEMI: Pharmacogenetic Anti-Platelet Therapy
NCT01452139Phase 3Completed
- Sponsor
- University of Ottawa Heart Institute
- Start
- Sep 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of prasugrel in ST-segment elevation myocardial infarction (STEMI) (3 arms), sponsored by University of Ottawa Heart Institute. Primary endpoint: Rates of high on-treatment platelet reactivity as measured by the VerifyNow P2Y12 assay at 1 month. Started Sep 2011; status: completed.
02
Drugs
prasugrel
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT01452139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01452139.